Mark Flather - Adamis Pharma IR Contact Officer
Executive
Mark Flather is IR Contact Officer of Adamis Pharma since 2018.
| Tenure | 7 years |
| Phone | 858 997 2400 |
| Web | https://www.adamispharmaceuticals.com |
Adamis Pharma Management Efficiency
The company has return on total asset (ROA) of (1.045) % which means that it has lost $1.045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.8496) %, meaning that it created substantial loss on money invested by shareholders. Adamis Pharma's management efficiency ratios could be used to measure how well Adamis Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Adamis Pharma currently holds 342.56 K in liabilities with Debt to Equity (D/E) ratio of 0.16, which may suggest the company is not taking enough advantage from borrowing. Adamis Pharma has a current ratio of 1.55, which is within standard range for the sector. Note, when we think about Adamis Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mitchell Gendel | Tilray Inc | 58 | |
| Mitchell JD | Tilray Inc | 59 | |
| Mark CPA | Evoke Pharma | 48 | |
| Jackie Klecker | Lifecore Biomedical | N/A | |
| Kara Morley | Lifecore Biomedical | N/A | |
| Darren Hieber | Lifecore Biomedical | N/A | |
| John Sadler | Tilray Inc | N/A | |
| Berrin Noorata | Tilray Inc | N/A | |
| Roger Savell | Tilray Inc | 63 | |
| MBA MD | Aquestive Therapeutics | 68 | |
| Carl MD | Aquestive Therapeutics | 55 | |
| DMD MD | Evoke Pharma | 76 | |
| Robert Arnold | Aquestive Therapeutics | N/A | |
| Timothy CPA | Shuttle Pharmaceuticals | 66 | |
| Steve Laninga | Lifecore Biomedical | N/A | |
| Cassie Jung | Aquestive Therapeutics | 46 | |
| Kenneth Marshall | Aquestive Therapeutics | 65 | |
| William CPA | Organogenesis Holdings | N/A | |
| Randy Daigneau | Tilray Inc | N/A | |
| Robert Cavorsi | Organogenesis Holdings | 46 | |
| Stephen Wargacki | Aquestive Therapeutics | 47 | |
Management Performance
| Return On Equity | -7.85 | |||
| Return On Asset | -1.04 |
Adamis Pharma Leadership Team
Elected by the shareholders, the Adamis Pharma's board of directors comprises two types of representatives: Adamis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adamis. The board's role is to monitor Adamis Pharma's management team and ensure that shareholders' interests are well served. Adamis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adamis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Marguglio, Sr. VP of Corporate Devel. and Director | ||
| Robert Rothermel, Consultant, Director, Chairman of Audit Committee, Member of Nominating and Governance Committee and Member of Compensation Committee | ||
| Karen Daniels, VP of Operations | ||
| Jennifer Suski, Director Marketing | ||
| Eddie Glover, Chief Inc | ||
| Mark Flather, IR Contact Officer | ||
| David Benedicto, Chief Officer |
Adamis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adamis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.85 | |||
| Return On Asset | -1.04 | |||
| Operating Margin | (3.74) % | |||
| Current Valuation | 7.28 M | |||
| Shares Outstanding | 9.36 M | |||
| Shares Owned By Insiders | 7.81 % | |||
| Shares Owned By Institutions | 16.59 % | |||
| Number Of Shares Shorted | 98.94 K | |||
| Price To Earning | (6.21) X | |||
| Price To Book | 8.62 X |
Pair Trading with Adamis Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adamis Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adamis Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Eastman Chemical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eastman Chemical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eastman Chemical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eastman Chemical to buy it.
The correlation of Eastman Chemical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eastman Chemical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eastman Chemical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eastman Chemical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Adamis Stock
If you are still planning to invest in Adamis Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adamis Pharma's history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |